Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

56.77 +0.85 (+1.52%)
Streaming Delayed Price Updated: 1:17 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
In the world of growth stocks, NASDAQ:CORT shines as a value proposition.
Looking for growth without the hefty price tag? Consider NASDAQ:CORT. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Earnings Preview: Corcept Therapeutics
Via Benzinga
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Key Takeaways From Corcept Therapeutics Analyst Ratings
Via Benzinga
Is NASDAQ:CORT suited for high growth investing?
Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing? 
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
NASDAQ:CORT is not too expensive for the growth it is showing. 
Via Chartmill
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Via Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced. 
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Unveiling 8 Analyst Insights On Corcept Therapeutics
Via Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating. 
Via Chartmill
6 Analysts Have This To Say About Corcept Therapeutics
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
Via InvestorPlace
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is showing good growth, while it is not too expensive. 
Via Chartmill
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.